Karin Holmskov Hansen

1.6k total citations · 1 hit paper
34 papers, 945 citations indexed

About

Karin Holmskov Hansen is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Karin Holmskov Hansen has authored 34 papers receiving a total of 945 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 25 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Karin Holmskov Hansen's work include Lung Cancer Treatments and Mutations (25 papers), Lung Cancer Research Studies (13 papers) and Colorectal Cancer Treatments and Studies (8 papers). Karin Holmskov Hansen is often cited by papers focused on Lung Cancer Treatments and Mutations (25 papers), Lung Cancer Research Studies (13 papers) and Colorectal Cancer Treatments and Studies (8 papers). Karin Holmskov Hansen collaborates with scholars based in Denmark, Spain and Netherlands. Karin Holmskov Hansen's co-authors include Olfred Hansen, Peter L. Sørensen, Marcello Tiseo, Rudolf M. Huber, Howard West, Karen L. Reckamp, Egbert F. Smit, Myung‐Ju Ahn, Harry J.M. Groen and Maximilian J. Hochmair and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Karin Holmskov Hansen

33 papers receiving 935 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

2017 430 citations Dong‐Wan Kim, Marcello Tiseo et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Karin Holmskov Hansen

Since Specialization

Citations

This map shows the geographic impact of Karin Holmskov Hansen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Holmskov Hansen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Holmskov Hansen more than expected).

Fields of papers citing papers by Karin Holmskov Hansen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Holmskov Hansen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Holmskov Hansen. The network helps show where Karin Holmskov Hansen may publish in the future.

Co-authorship network of co-authors of Karin Holmskov Hansen

This figure shows the co-authorship network connecting the top 25 collaborators of Karin Holmskov Hansen. A scholar is included among the top collaborators of Karin Holmskov Hansen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karin Holmskov Hansen. Karin Holmskov Hansen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Remote Symptom Monitoring of Patients With Advanced Lung Cancer (The ProWide Study): A Randomized Controlled Trial 2024 ·JCO Oncology Practice ·(unknown), Helle Pappot, Niels Henrik Hjøllund, (unknown), (unknown), Gitte Fredberg Persson, (unknown), (unknown), (unknown), Karin Holmskov Hansen, Torben Riis Rasmussen, Susanne Oksbjerg Dalton, Erik Jakobsen, (unknown), Halla Skúladóttir, (unknown)	1
2	5-Year survival in Danish patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy 2023 ·Acta Oncologica ·(unknown), (unknown), Charlotte Kristiansen, Tine Schytte, (unknown), Mette Pøhl, Karin Holmskov Hansen	6
3	ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial 2023 ·BMC Cancer ·(unknown), Martin Højgaard, Kristoffer Staal Rohrberg, Iben Spanggaard, Britt Elmedal Laursen, Morten Ladekarl, Charlotte Aaquist Haslund, Laurine Bente Schram Harsløf, (unknown), Julie Gehl, Lise Søndergaard, Rikke Løvendahl Eefsen, Karin Holmskov Hansen, Annette Raskov Kodahl, Lars Henrik Jensen, Marianne Ingerslev Holt, (unknown), Christina W. Yde, Lise Barlebo Ahlborn, Ulrik Lassen	11
4	Clinical impact of venous thromboembolism in non-small cell lung cancer patients receiving immunotherapy 2022 ·Thrombosis Research ·(unknown), Charlotte Kristiansen, Jon Thor Asmussen, Karin Holmskov Hansen, (unknown), Trine Lembrecht Jørgensen, Jørn Herrstedt, Tine Schytte	9
5	Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis 2022 ·Cancers ·(unknown), Karin Holmskov Hansen, Jon Thor Asmussen, Trine Lembrecht Jørgensen, Jørn Herrstedt, Tine Schytte	6
6	Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials 2022 ·Translational Lung Cancer Research ·(unknown), (unknown), Åslaug Helland, Simon Ekman, Anders Mellemgaard, Karin Holmskov Hansen, Saulius Cicėnas, Jussi Koivunen, Bjørn Henning Grønberg, Boe Sandahl Sørensen, Odd Terje Brustugun	12
7	How to select cancer patients for immunotherapy 2021 ·EBioMedicine ·Per Pfeiffer, Camilla Qvortrup, Karin Holmskov Hansen	3
8	Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study) 2020 ·Lung Cancer ·(unknown), Åslaug Helland, Simon Ekman, Anders Mellemgaard, Karin Holmskov Hansen, Saulius Cicėnas, Jussi Koivunen, Bjørn Henning Grønberg, Odd Terje Brustugun	43
9	1334P Real word experience with first-line immunotherapy in advanced non-small cell lung cancer patients in a Danish nationwide cohort 2020 ·Annals of Oncology ·(unknown), (unknown), Mette Poehl, Morten Ladekarl, (unknown), (unknown), (unknown), Peter Meldgaard, Karin Holmskov Hansen, (unknown), Charlotte Kristiansen, (unknown), (unknown), (unknown), Gitte Fredberg Persson, (unknown), (unknown), Andreas Carus	1
10	1333P The influence of polypharmacy on outcome in real life non-small cell lung cancer (NSCLC) patients treated with immunotherapy 2020 ·Annals of Oncology ·(unknown), Karin Holmskov Hansen, Trine Lembrecht Jørgensen, Jørn Herrstedt, Tine Schytte	2
11	Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients 2020 ·Lung Cancer ·(unknown), (unknown), Karin Holmskov Hansen, (unknown), Boe Sandahl Sørensen, Peter Meldgaard	18
12	Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study 2019 ·Acta Oncologica ·(unknown), Karin Holmskov Hansen, Trine Lembrecht Jørgensen, Jørn Herrstedt, Tine Schytte	36
13	EP1.04-29 Khorana Score: A Potential New Biomarker for Real Life Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Immunotherapy 2019 ·Journal of Thoracic Oncology ·(unknown), Karin Holmskov Hansen, Trine Lembrecht Jørgensen, Jørn Herrstedt, Tine Schytte	1
14	Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer 2019 ·Lung Cancer ·(unknown), (unknown), Karin Holmskov Hansen, (unknown), Boe Sandahl Sørensen, Peter Meldgaard	31
15	Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial 2019 ·Journal of Thoracic Oncology ·Rudolf M. Huber, Karin Holmskov Hansen, Luis Paz-Ares Rodríguez, Howard West, Karen L. Reckamp, Natasha B. Leighl, Marcello Tiseo, Egbert F. Smit, Dong‐Wan Kim, Scott Gettinger, Maximilian J. Hochmair, Sang-We Kim, Corey J. Langer, Myung‐Ju Ahn, Edward S. Kim, David Kerstein, Harry J.M. Groen, D. Ross Camidge	101
16	Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial breakdown → 2017 ·Journal of Clinical Oncology ·Dong‐Wan Kim, Marcello Tiseo, Myung‐Ju Ahn, Karen L. Reckamp, Karin Holmskov Hansen, Sang‐We Kim, Rudolf M. Huber, Howard West, Harry J.M. Groen, Maximilian J. Hochmair, Natasha B. Leighl, Scott Gettinger, Corey J. Langer, (unknown), Egbert F. Smit, Edward S. Kim, William M. Reichmann, Frank G. Haluska, David Kerstein, D. Ross Camidge	430
17	Brigatinib (BRG) in Crizotinib (CRZ)-Refractory ALK+ Non–Small Cell Lung Cancer (NSCLC): efficacy and safety results from ALTA, a pivotal randomized phase 2 Trial 2016 ·Annals of Oncology ·(unknown), Marcello Tiseo, Myung‐Ju Ahn, Karen L. Reckamp, Karin Holmskov Hansen, (unknown), Rudolf M. Huber, Howard West, Harry J.M. Groen, Maximilian J. Hochmair, Natasha B. Leighl, Scott Gettinger, Corey J. Langer, Luis Paz-Ares Rodríguez, Egbert F. Smit, William M. Reichmann, David Kerstein, Frank G. Haluska, D. Ross Camidge	1
18	Trends in lung cancer in elderly in Denmark, 1980–2012 2016 ·Acta Oncologica ·Charlotte Kristiansen, Tine Schytte, Karin Holmskov Hansen, Eva Holtved, Olfred Hansen	12
19	The occurrence of hyponatremia in SCLC and the influence on prognosis 2009 ·Lung Cancer ·Olfred Hansen, Peter L. Sørensen, Karin Holmskov Hansen	109
20	Absence of hydrocephalus in spite of impaired cerebrospinal fluid absorption and severe intracranial hypertension 1987 ·Acta Neurochirurgica ·Karin Holmskov Hansen, F. Gjerris, P. S. S�rensen	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact